Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET James Markmann - Corporate Participant Michael ...

Vertex Pharmaceuticals has been making quiet waves lately, popping up on investors’ radars like a biotech whack-a-mole. With ...

Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...